StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Investment analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Several other equities research analysts have also commented on VNRX. D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Tuesday, December 10th. Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Price Performance

VolitionRx stock opened at $0.61 on Friday. The company has a market cap of $56.81 million, a PE ratio of -1.70 and a beta of 1.17. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23. The company has a fifty day moving average price of $0.67 and a two-hundred day moving average price of $0.66.

Insider Buying and Selling

In other news, Director Guy Archibald Innes bought 174,764 shares of VolitionRx stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 358,266 shares of company stock valued at $204,212. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC raised its position in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.